• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Antiviral treatment for Bell's palsy (idiopathic facial paralysis).贝尔氏面瘫(特发性面神经麻痹)的抗病毒治疗。
Cochrane Database Syst Rev. 2019 Sep 5;9(9):CD001869. doi: 10.1002/14651858.CD001869.pub9.
2
Antiviral treatment for Bell's palsy (idiopathic facial paralysis).贝尔氏面瘫(特发性面神经麻痹)的抗病毒治疗。
Cochrane Database Syst Rev. 2015 Jul 1(7):CD001869. doi: 10.1002/14651858.CD001869.pub6.
3
Antiviral treatment for Bell's palsy (idiopathic facial paralysis).贝尔氏麻痹(特发性面神经麻痹)的抗病毒治疗。
Cochrane Database Syst Rev. 2015 Nov 9(11):CD001869. doi: 10.1002/14651858.CD001869.pub8.
4
WITHDRAWN. Antiviral treatment for Bell's palsy (idiopathic facial paralysis).撤回。贝尔麻痹(特发性面神经麻痹)的抗病毒治疗。
Cochrane Database Syst Rev. 2015 May 4(5):CD001869. doi: 10.1002/14651858.CD001869.pub5.
5
Antiviral treatment for Bell's palsy (idiopathic facial paralysis).贝尔氏面瘫(特发性面神经麻痹)的抗病毒治疗。
Cochrane Database Syst Rev. 2009 Oct 7(4):CD001869. doi: 10.1002/14651858.CD001869.pub4.
6
Corticosteroids for Bell's palsy (idiopathic facial paralysis).用于贝尔氏面瘫(特发性面神经麻痹)的皮质类固醇
Cochrane Database Syst Rev. 2016 Jul 18;7(7):CD001942. doi: 10.1002/14651858.CD001942.pub5.
7
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
8
Physical therapy for Bell's palsy (idiopathic facial paralysis).贝尔氏面瘫(特发性面神经麻痹)的物理治疗
Cochrane Database Syst Rev. 2011 Dec 7(12):CD006283. doi: 10.1002/14651858.CD006283.pub3.
9
WITHDRAWN: Aciclovir or valaciclovir for Bell's palsy (idiopathic facial paralysis).撤回:阿昔洛韦或伐昔洛韦用于贝尔麻痹(特发性面神经麻痹)。
Cochrane Database Syst Rev. 2009 Apr 15(2):CD001869. doi: 10.1002/14651858.CD001869.pub3.
10
Aciclovir or valaciclovir for Bell's palsy (idiopathic facial paralysis).阿昔洛韦或伐昔洛韦用于治疗贝尔麻痹(特发性面神经麻痹)。
Cochrane Database Syst Rev. 2004(3):CD001869. doi: 10.1002/14651858.CD001869.pub2.

引用本文的文献

1
Ophthalmic and periocular management of facial nerve palsy.面神经麻痹的眼科及眼周治疗
Saudi J Ophthalmol. 2025 Feb 24;39(2):117-124. doi: 10.4103/sjopt.sjopt_3_25. eCollection 2025 Apr-Jun.
2
Assessment of Diagnostic Knowledge and the Management of Bell's Palsy Among Primary HealthCare Physicians in Saudi Arabia.沙特阿拉伯初级医疗保健医生对贝尔麻痹的诊断知识及管理评估
Risk Manag Healthc Policy. 2025 May 2;18:1493-1502. doi: 10.2147/RMHP.S514912. eCollection 2025.
3
Exploring the Role of Inflammation and Metabolites in Bell's Palsy and Potential Treatment Strategies.探索炎症和代谢产物在贝尔面瘫中的作用及潜在治疗策略。
Biomedicines. 2025 Apr 13;13(4):957. doi: 10.3390/biomedicines13040957.
4
Advances in the Research of Mesenchymal Stromal Cells in the Treatment of Maxillofacial Neurological Disorders and the Promotion of Facial Nerve Regeneration.间充质基质细胞治疗颌面部神经疾病及促进面神经再生的研究进展
Mol Neurobiol. 2025 Apr 28. doi: 10.1007/s12035-025-04981-8.
5
Update on Medical Management of Acute Peripheral Facial Palsy.急性周围性面瘫的医学管理最新进展
J Audiol Otol. 2025 Jan;29(1):1-7. doi: 10.7874/jao.2024.00731. Epub 2025 Jan 20.
6
Bell's palsy characteristics, clinical manifestations, complications, and prognosis in a primary care setting, a single center study: A retrospective cohort study.基层医疗环境中贝尔麻痹的特征、临床表现、并发症及预后:一项单中心回顾性队列研究
J Family Med Prim Care. 2024 Nov;13(11):5067-5071. doi: 10.4103/jfmpc.jfmpc_664_24. Epub 2024 Nov 18.
7
Effect of Intratympanic Dexamethasone on Bell's palsy: A Clinical Trial.鼓室内注射地塞米松对贝尔面瘫的影响:一项临床试验
Iran J Otorhinolaryngol. 2024;36(6):631-637. doi: 10.22038/ijorl.2024.74635.3510.
8
Exploring Non-invasive Therapies for Bell's Palsy: A Case Report.探索贝尔麻痹的非侵入性治疗方法:一例病例报告。
Cureus. 2024 Jun 24;16(6):e63071. doi: 10.7759/cureus.63071. eCollection 2024 Jun.
9
Predictive Value of the Neutrophil-to-Lymphocyte Ratio and C-Reactive Protein in Patients with Idiopathic Facial Nerve Palsy.中性粒细胞与淋巴细胞比值及C反应蛋白在特发性面神经麻痹患者中的预测价值
Int J Gen Med. 2024 Jun 7;17:2635-2642. doi: 10.2147/IJGM.S458808. eCollection 2024.
10
Effectiveness of novel facial stretching with structured exercise versus conventional exercise for Bell's palsy: a single-blinded randomized clinical trial.新型面部拉伸结合结构性运动与传统运动治疗贝尔麻痹的疗效比较:一项单盲随机临床试验。
Sci Rep. 2024 Jun 10;14(1):13266. doi: 10.1038/s41598-024-64046-z.

本文引用的文献

1
A Network Meta-Analysis to Compare the Efficacy of Steroid and Antiviral Medications for Facial Paralysis from Bell´s Palsy.一项网络荟萃分析比较了类固醇和抗病毒药物治疗贝尔氏面瘫所致面瘫的疗效。
Pain Physician. 2018 Nov;21(6):559-569.
2
Bell's Palsy in Children (BellPIC): protocol for a multicentre, placebo-controlled randomized trial.儿童贝尔麻痹(BellPIC):一项多中心、安慰剂对照随机试验的方案
BMC Pediatr. 2017 Feb 13;17(1):53. doi: 10.1186/s12887-016-0702-y.
3
Steroid/Antiviral for the treatment of Bell's palsy: Double blind randomized clinical trial.类固醇/抗病毒药物治疗贝尔氏面瘫:双盲随机临床试验
Restor Neurol Neurosci. 2016 Nov 22;34(6):897-905. doi: 10.3233/RNN-150605.
4
Corticosteroids for Bell's palsy (idiopathic facial paralysis).用于贝尔氏面瘫(特发性面神经麻痹)的皮质类固醇
Cochrane Database Syst Rev. 2016 Jul 18;7(7):CD001942. doi: 10.1002/14651858.CD001942.pub5.
5
Are corticosteroids useful in all degrees of severity and rapid recovery of Bell's palsy?皮质类固醇对所有严重程度的贝尔面瘫及快速恢复都有用吗?
Acta Otolaryngol. 2016 Jul;136(7):736-41. doi: 10.3109/00016489.2016.1154604. Epub 2016 Mar 22.
6
Antiviral treatment for Bell's palsy (idiopathic facial paralysis).贝尔氏麻痹(特发性面神经麻痹)的抗病毒治疗。
Cochrane Database Syst Rev. 2015 Nov 9(11):CD001869. doi: 10.1002/14651858.CD001869.pub8.
7
Comparison of the Efficacy of Combination Therapy of Prednisolone - Acyclovir with Prednisolone Alone in Bell's Palsy.泼尼松龙联合阿昔洛韦与单用泼尼松龙治疗贝尔面瘫的疗效比较。
Iran J Child Neurol. 2015 Spring;9(2):17-20.
8
Antiviral treatment for Bell's palsy (idiopathic facial paralysis).贝尔氏面瘫(特发性面神经麻痹)的抗病毒治疗。
Cochrane Database Syst Rev. 2015 Jul 1(7):CD001869. doi: 10.1002/14651858.CD001869.pub6.
9
WITHDRAWN. Antiviral treatment for Bell's palsy (idiopathic facial paralysis).撤回。贝尔麻痹(特发性面神经麻痹)的抗病毒治疗。
Cochrane Database Syst Rev. 2015 May 4(5):CD001869. doi: 10.1002/14651858.CD001869.pub5.
10
Steroid-antivirals treatment versus steroids alone for the treatment of Bell's palsy: a meta-analysis.类固醇-抗病毒药物联合治疗与单独使用类固醇治疗贝尔面瘫的疗效比较:一项荟萃分析。
Int J Clin Exp Med. 2015 Jan 15;8(1):413-21. eCollection 2015.

贝尔氏面瘫(特发性面神经麻痹)的抗病毒治疗。

Antiviral treatment for Bell's palsy (idiopathic facial paralysis).

作者信息

Gagyor Ildiko, Madhok Vishnu B, Daly Fergus, Sullivan Frank

机构信息

Department of General Practice, Universitätsklinikum Würzburg, Josef-Schneider-Straße 2, Würzburg, Bavaria, Germany, 97080.

出版信息

Cochrane Database Syst Rev. 2019 Sep 5;9(9):CD001869. doi: 10.1002/14651858.CD001869.pub9.

DOI:10.1002/14651858.CD001869.pub9
PMID:31486071
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6726970/
Abstract

BACKGROUND

Corticosteroids are widely used in the treatment of idiopathic facial paralysis (Bell's palsy), but the effectiveness of additional treatment with an antiviral agent is uncertain. This review was first published in 2001 and most recently updated in 2015. Since a significant benefit of corticosteroids for the early management of Bell's palsy has been demonstrated, the main focus of this update, as in the previous version, was to determine the effect of adding antivirals to corticosteroid treatment. We undertook this update to integrate additional evidence and to better assess the robustness of findings, taking risk of bias fully into account.

OBJECTIVES

To assess the effects of antiviral treatments alone or in combination with any other therapy for Bell's palsy.

SEARCH METHODS

We searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS in July 2019. We reviewed the bibliographies of the identified trials and contacted trial authors to identify additional published or unpublished data. We searched clinical trials registries for ongoing studies.

SELECTION CRITERIA

We considered randomised controlled trials (RCTs) or quasi-RCTs of antivirals with and without corticosteroids versus control therapies for the treatment of Bell's palsy. We excluded trials that followed-up participants for less than three months.

DATA COLLECTION AND ANALYSIS

We independently assessed trials for relevance, eligibility, and risk of bias, using standard Cochrane procedures. We performed sensitivity analyses excluding trials at high or unclear risk of bias in at least five domains, and reported these data as the primary analyses.

MAIN RESULTS

Fourteen trials, including 2488 participants, met the inclusion criteria. Most were small, and most were at high or unclear risk of bias in multiple domains. We included four new studies at this update.Incomplete recoveryA combination of antivirals and corticosteroids may have little or no effect on rates of incomplete recovery in people with Bell's palsy compared to corticosteroids alone (risk ratio (RR) 0.81, 95% confidence interval (CI) 0.38 to 1.74; 3 trials, N = 766; random-effects; low-certainty evidence). We excluded 10 trials that were at high or unclear risk of bias in several domains from this analysis and limited all analyses to studies at lower risk of bias. Recovery rates were better in participants receiving corticosteroids alone than antivirals alone (RR 2.69, 95% CI 0.73 to 10.01; 2 trials, N = 667; random-effects), but the result was imprecise and allowed for the possibility of no effect. The rate of incomplete recovery was lower with antivirals plus corticosteroids than with placebo or no treatment (RR 0.56, 95% CI 0.42 to 0.76; 2 trials, N = 658; random-effects). Antivirals alone had no clear effect on incomplete recovery rates compared with placebo, but the result was imprecise (RR 1.10, 95% CI 0.87 to 1.40; 2 trials, N = 658; fixed-effect). For people with severe Bell's palsy (House-Brackmann score of 5 and 6, or equivalent on other scales), we found that the combination of antivirals and corticosteroids had no clear effect on incomplete recovery at month six compared to corticosteroids alone, although the result was again imprecise (RR 0.82, 95% CI 0.57 to 1.17; 2 trials, N = 98; random-effects).Motor synkinesis or crocodile tearsAntivirals plus corticosteroids reduced the proportion of participants who experienced these long-term sequelae from Bell's palsy compared to placebo plus corticosteroids (RR 0.56, 95% CI 0.36 to 0.87; 2 trials, N = 469; fixed-effect; moderate-certainty evidence). Antivirals plus corticosteroids reduced long-term sequelae compared to placebo but there was no clear difference in this outcome with antivirals alone compared to placebo.Adverse events Adverse event data were available in four studies providing data on 1592 participants. None of the four comparisons showed clear differences in adverse events between treatment and comparison arms (very low-certainty evidence); for the comparison of antivirals plus corticosteroids and corticosteroids alone in studies at lower risk of bias, the RR was 1.17 (95% CI 0.81 to 1.69; 2 trials, N = 656; fixed-effect; very low-certainty evidence).

AUTHORS' CONCLUSIONS: The combination of antivirals and corticosteroids may have little or no effect on rates of incomplete recovery in comparison to corticosteroids alone in Bell's palsy of various degrees of severity, or in people with severe Bell's palsy, but the results were very imprecise. Corticosteroids alone were probably more effective than antivirals alone and antivirals plus corticosteroids were more effective than placebo or no treatment. There was no clear benefit from antivirals alone over placebo.The combination of antivirals and corticosteroids probably reduced the late sequelae of Bell's palsy compared with corticosteroids alone. Studies also showed fewer episodes of long-term sequelae in corticosteroid-treated participants than antiviral-treated participants.We found no clear difference in adverse events from the use of antivirals compared with either placebo or corticosteroids, but the evidence is too uncertain for us to draw conclusions.An adequately powered RCT in people with Bell's palsy that compares different antiviral agents may be indicated.

摘要

背景

皮质类固醇广泛用于治疗特发性面神经麻痹(贝尔麻痹),但联合使用抗病毒药物的有效性尚不确定。本综述首次发表于2001年,最近一次更新于2015年。由于已证明皮质类固醇对贝尔麻痹的早期治疗有显著益处,本次更新的主要重点,与上一版一样,是确定在皮质类固醇治疗中添加抗病毒药物的效果。我们进行本次更新是为了整合更多证据,并在充分考虑偏倚风险的情况下,更好地评估研究结果的稳健性。

目的

评估单独使用抗病毒治疗或与其他任何疗法联合用于贝尔麻痹的效果。

检索方法

我们于2019年7月检索了Cochrane神经肌肉专业注册库、CENTRAL、MEDLINE、Embase和LILACS。我们查阅了已识别试验的参考文献,并联系试验作者以识别其他已发表或未发表的数据。我们检索临床试验注册库以查找正在进行的研究。

选择标准

我们纳入了将使用和不使用皮质类固醇的抗病毒药物与对照疗法进行比较以治疗贝尔麻痹的随机对照试验(RCT)或半随机对照试验。我们排除了随访参与者少于三个月的试验。

数据收集与分析

我们使用Cochrane标准程序独立评估试验的相关性、纳入标准和偏倚风险。我们进行了敏感性分析,排除了至少五个领域偏倚风险高或不明确的试验,并将这些数据作为主要分析结果报告。

主要结果

14项试验,包括2488名参与者,符合纳入标准。大多数试验规模较小,且在多个领域偏倚风险高或不明确。本次更新纳入了四项新研究。

不完全恢复

与单独使用皮质类固醇相比,抗病毒药物与皮质类固醇联合使用对贝尔麻痹患者不完全恢复率可能几乎没有影响或无影响(风险比(RR)0.81,95%置信区间(CI)0.38至1.74;3项试验,N = 766;随机效应;低确定性证据)。我们在本次分析中排除了10项在多个领域偏倚风险高或不明确的试验,并将所有分析限制在偏倚风险较低的研究中。单独接受皮质类固醇治疗的参与者的恢复率优于单独接受抗病毒药物治疗的参与者(RR 2.69,95% CI 0.73至10.01;2项试验,N = 667;随机效应),但结果不精确,且可能无效果。与安慰剂或不治疗相比,抗病毒药物加皮质类固醇的不完全恢复率更低(RR 0.56,95% CI 0.42至0.76;2项试验,N = 658;随机效应)。与安慰剂相比,单独使用抗病毒药物对不完全恢复率没有明确影响,但结果不精确(RR 1.10,95% CI 0.87至1.40;2项试验,N = 658;固定效应)。对于重度贝尔麻痹患者(House - Brackmann评分为5和6,或其他量表上的等效评分),我们发现与单独使用皮质类固醇相比,抗病毒药物与皮质类固醇联合使用在第6个月时对不完全恢复没有明确影响,尽管结果同样不精确(RR 0.82,95% CI 0.57至1.17;2项试验,N = 98;随机效应)。

运动联带运动或鳄鱼泪

与安慰剂加皮质类固醇相比,抗病毒药物加皮质类固醇可降低贝尔麻痹患者出现这些长期后遗症的参与者比例(RR 0.56,95% CI 0.36至0.87;2项试验,N = 469;固定效应;中度确定性证据)。与安慰剂相比,抗病毒药物加皮质类固醇可减少长期后遗症,但单独使用抗病毒药物与安慰剂相比,此结果无明显差异。

不良事件

四项研究提供了1592名参与者的不良事件数据。四项比较中均未显示治疗组和对照组之间在不良事件方面有明显差异(极低确定性证据);对于偏倚风险较低的研究中抗病毒药物加皮质类固醇与单独使用皮质类固醇的比较,RR为1.17(95% CI 0.81至1.69;2项试验,N = 656;固定效应;极低确定性证据)。

作者结论

在不同严重程度的贝尔麻痹患者或重度贝尔麻痹患者中,与单独使用皮质类固醇相比,抗病毒药物与皮质类固醇联合使用对不完全恢复率可能几乎没有影响或无影响,但结果非常不精确。单独使用皮质类固醇可能比单独使用抗病毒药物更有效,且抗病毒药物加皮质类固醇比安慰剂或不治疗更有效。单独使用抗病毒药物与安慰剂相比没有明显益处。与单独使用皮质类固醇相比,抗病毒药物与皮质类固醇联合使用可能减少了贝尔麻痹的晚期后遗症。研究还表明,接受皮质类固醇治疗的参与者长期后遗症发作次数少于接受抗病毒药物治疗的参与者。我们发现与安慰剂或皮质类固醇相比,使用抗病毒药物的不良事件没有明显差异,但证据过于不确定,我们无法得出结论。可能需要进行一项针对贝尔麻痹患者的有足够样本量的RCT,比较不同的抗病毒药物。